Related Experiment Video
Updated: May 10, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
[Tardive dyskinesia: diagnosis, assessment and treatment]
Marianna Frascarelli1, Marco Paolemili, Mariana Gallo
1Dipartimento di Neurologia e Psichiatria, Sapienza Università di Roma.
Abstract:
Tardive dyskinesia is a potentially fatal side effect of antipsychotics. In the classic form is characterized by involuntary hyperkinetic movements, especially those affecting the mimic and mastication muscles. The main hypothesis considers that the pathophysiological basis of the disorder is an overexpression of D2 receptors in the striatum, in response to dopamine block neuroleptics-mediated, especially the older ones. Because fortunately not all patients undergo this severe adverse effects, many efforts have been conducted in trying to delineate the risk factors so as to try to prevent tardive dyskinesia by administering lower doses of neuroleptics in vulnerable groups. Advanced age, female sex, smoking habits, diabetes mellitus, alcohol abuse are known as risk factors. The instead the role of the type of psychiatric disorder, instead, is still debated. Since there was a direct relationship between cumulative dose of antipsychotic and treatment duration, recent studies are aimed at identifying factors that contribute to increased plasma concentrations of the drug, such as genetic polymorphisms of metabolizer enzymes that encode for enzymatic variants with decreased activity.
Insights
Tardive dyskinesia, a severe antipsychotic side effect, involves involuntary movements. Research identifies risk factors like age, sex, and substance abuse, and explores genetic influences on drug metabolism to prevent this condition.
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Context:
- Tardive dyskinesia is a serious adverse effect of antipsychotic medications.
- It manifests as involuntary hyperkinetic movements, particularly affecting facial muscles.
Purpose:
- To identify risk factors for tardive dyskinesia.
- To explore the pathophysiological basis, including D2 receptor changes and genetic factors.
Summary:
- The disorder is linked to D2 receptor overexpression in the striatum due to dopamine blockade.
- Known risk factors include advanced age, female sex, smoking, diabetes, and alcohol abuse.
- Genetic polymorphisms affecting drug metabolism enzymes are being investigated for their role in increased drug concentrations.
Impact:
- Understanding risk factors may allow for preventative strategies, such as dose reduction in vulnerable populations.
- Identifying genetic predispositions could personalize antipsychotic treatment and minimize tardive dyskinesia risk.
- This research contributes to safer antipsychotic therapy and improved patient outcomes.
More Related Videos
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment
Parkinson's Disease: Overview
Drug Therapy
Antianxiety Medications
Dysrhythmias VII: Nursing Management of Dysrhythmias
Alterations in Muscle Tone lll

